MENU
+Compare
NRIX
Stock ticker: NASDAQ
AS OF
Feb 21 closing price
Price
$16.87
Change
-$0.17 (-1.00%)
Capitalization
1.28B

NRIX Nurix Therapeutics Forecast, Technical & Fundamental Analysis

a biopharmaceutical company, which focuses on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders

Industry Biotechnology
NRIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for NRIX with price predictions
Feb 18, 2025

NRIX in upward trend: price may jump up because it broke its lower Bollinger Band on February 10, 2025

NRIX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 32 cases where NRIX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for NRIX's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NRIX advanced for three days, in of 252 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on February 03, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on NRIX as a result. In of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for NRIX turned negative on February 07, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at .

The 50-day moving average for NRIX moved below the 200-day moving average on January 29, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRIX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for NRIX entered a downward trend on January 23, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.432) is normal, around the industry mean (12.604). P/E Ratio (0.000) is within average values for comparable stocks, (85.387). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.581). NRIX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (20.790) is also within normal values, averaging (252.111).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NRIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
NRIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

NRIX is expected to report earnings to rise 3.71% to -77 cents per share on April 09

Nurix Therapeutics NRIX Stock Earnings Reports
Q1'25
Est.
$-0.78
Q4'24
Missed
by $0.07
Q3'24
Est.
$-0.67
Q2'24
Missed
by $0.08
Q1'24
Beat
by $0.02
The last earnings report on January 28 showed earnings per share of -75 cents, missing the estimate of -68 cents. With 524.36K shares outstanding, the current market capitalization sits at 1.28B.
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which focuses on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
1700 Owens Street
Phone
+1 415 660-5320
Employees
284
Web
http://www.nurixtx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPY611.491.79
+0.29%
SPDR® S&P 500® ETF Trust
AAPL244.47-0.13
-0.05%
Apple
GME26.97-0.03
-0.11%
GameStop Corp
BTC.X95539.550000-233.835940
-0.24%
Bitcoin cryptocurrency
TSLA354.11-1.73
-0.49%
Tesla

NRIX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NRIX has been loosely correlated with DNLI. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if NRIX jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NRIX
1D Price
Change %
NRIX100%
-4.89%
DNLI - NRIX
45%
Loosely correlated
+1.97%
KYMR - NRIX
45%
Loosely correlated
+0.68%
CCCC - NRIX
42%
Loosely correlated
-6.60%
LYEL - NRIX
40%
Loosely correlated
-0.11%
BEAM - NRIX
40%
Loosely correlated
+3.36%
More